
Insulet Revenue Surges 33.9% as International Omnipod Sales Skyrocket
Insulet CorporationDescription
What this story covers
Insulet Corporation reported exceptional Q1 2026 results, with revenue hitting $761.7 million. Driven by massive international growth and Omnipod 5 adoption, the company raised its full-year guidance and demonstrated strong profitability with a 73% increase in free cash flow.
Story snapshot
CompanyInsulet Corporation
TickerPODD
VariantStandard detailed
Duration12:39
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001145197-26-000100
Sources1
Full Story Script
Content not available for this story.